Lexaria Bioscience (LEXX) Invested Capital (2010 - 2026)

Lexaria Bioscience has disclosed Invested Capital across 17 years of filings, most recently posting $6.6 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $6.6 million, down 2.34% year-over-year; the trailing twelve-month figure through Feb 2026 was $6.6 million (down 2.34% YoY), and the FY2025 annual result was $3.0 million, down 60.97% from the prior year.
• Invested Capital came in at $6.6 million for Q1 2026 at Lexaria Bioscience, up from $4.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $11.2 million in Q1 2022 to a low of $2.7 million in Q3 2023.
• The 5-year median for Invested Capital is $6.1 million (2024), against an average of $6.3 million.
• Across the five-year window, Invested Capital sank 64.89% in 2023 and surged 185.78% in 2024, its largest moves.
• Lexaria Bioscience's Invested Capital stood at $5.9 million in 2022, then plunged by 43.14% to $3.4 million in 2023, then jumped by 178.53% to $9.4 million in 2024, then slumped by 51.85% to $4.5 million in 2025, then jumped by 45.96% to $6.6 million in 2026.
• The last three Invested Capital figures came in at $6.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.